Dogwood Therapeutics Q3 net loss $2.3M; cash runway depends on $3M Feb 2025 tranche

Dogwood Therapeutics, Inc.

2024-Q3 EPS reported -$4.95

Net loss $2.3M ($2.05/share) vs $1.2M ($1.62) in Q3 2023; R&D and G&A expenses rose.
Cash $2.0M at Sep 30; $16.5M loan from CKLS affiliate received Oct 7; $3M tranche needed Feb 2025 to fund through 2025.
Top-line results from IMC-2 Long-COVID Phase 2a study expected mid-November 2024.
Halneuron Phase 2b CINP interim data expected 2H 2025; FDA fast-track designation granted.
Company formed via combination of Virios and Pharmagesic; pipeline includes IMC-1, IMC-2, and Halneuron.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.